Market research analysis industry Immuno-Oncology Market, By Type [mAb (Naked, Conjugate), Cancer Vaccines, Immune Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4]), By Application (Lung, Melanoma, Leukemia, Lymphoma) - Global Forecast to 2024 latest reports company India

Immuno-Oncology Market, By Type [mAb (Naked, Conjugate), Cancer Vaccines, Immune Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4]), By Application (Lung, Melanoma, Leukemia, Lymphoma) - Global Forecast to 2024

Format : Adobe Reader (PDF) Upto 24 hour delivery
Publish Date : Oct, 2020| No. of Pages : 195

Share |

Please make your selection :

Electronic Access - Single User License

US$ 3000.00

CD-ROM Mail Delivery

US$ 3500.00

Hard Copy Mail Delivery

US$ 3500.00

Electronic Access - Multi-User License

US$ 6000.00

1. Analyst View

2. Research Methodology

3. Immuno-Oncology: Overview

4. Market Dynamics

4.1 Drivers

4.1.1 Increasing Cancer Incidences

4.1.2 Immune Checkpoint Inhibitors Sales Driving the Market Growth

4.1.3 Growing Geriatric Population

4.1.4 High Healthcare Spending in Developed Economies

4.1.5 Strong Pipeline

4.1.6 Increasing Efficacy in a Wide Variety of Indications

4.1.7 Burgeoning Approval and Uptake of Immuno-Oncology Products

4.2 Challenges

4.2.1 Patent Expiry of Top-Selling Drugs

4.2.2 Increasing Number of Side-Effects Post Immunotherapy Treatments

4.2.3 Sky-High Development Costs of Cancer Immunotherapies

4.2.4 High Cost of Treatment

4.2.5 Lack of Awareness

4.3 Opportunities

4.3.1 Opdivo and Keytruda Presents Significant Growth Opportunity

4.3.2 Combination Therapies Could Lead to Substantial Increases in Survival

4.3.3 CAR-T Therapies: The Future of Cancer Care

4.3.4 Small Companies Offering Huge Opportunites for Next Generation Immunotherapies

5. Global Immuno-Oncology Market Outlook 2024

6. Global Immuno-Oncology Market, by Product Class

6.1 Monoclonal Antibodies (mAbs)

6.1.1 Naked Monoclonal Antibodies

6.1.1.1 Rituxan (Rituximab)

6.1.1.2 Avastin (Bevacizumab)

6.1.1.3 Herceptin (Trastuzumab)

6.1.2 Conjugated Monoclonal Antibodies

6.1.2.1 ADCETRIS (Brentuximab vedotin)

6.1.2.2 Kadcyla (Ado-trastuzumab emtansine/TDM-1)

6.1.3 Bispecific Monoclonal Antibodies

6.1.3.1 Blincyto (Blinatumomab)

6.1.4 Others

6.2 Therapeutic Vaccines

6.2.1 Provenge

6.3 Immune Checkpoint Inhibitors

6.3.1 CTLA-4 Inhibitors (Cytotoxic T-Lymphocyte-Associated Protein-4)

6.3.1.1 Yervoy (Ipilimumab)

6.3.2 PD-1 and PD-L1 Inhibitors(Programmed Death 1 and Programmed Death Ligand

6.3.2.1 Opdivo (Nivolumab)

6.3.2.2 Keytruda (Pembrolizumab)

6.4 Others

7. Global Immuno-Oncology Market, By Major Indications

7.1 Head & Neck Cancer

7.2 Lung Cancer

7.3 Melanoma

7.4 Lymphoma

7.5 Leukemia

7.6 Others

8. Global Immuno-Oncology Market, By Geography

8.1 North America

8.2 Europe

8.3 Asia-Pacific

9. Trends & Developments

9.1 Lucrative Investment Trend

9.2 Emergence of Targeted and Combination Therapies

9.3 NSCLC & Melanoma Showing Greatest Contributions to the IO Market

10. Strategic Collaborations & Alliances in the Immuno-Oncology Industry

11. Pipeline Analysis of Immuno-Oncology

12. Competitive Landscape

12.1 Share of Major Players

13. Key Players Analysis

13.1 F. Hoffmann-La Roche AG

13.2 Bristol-Myers Squibb

13.3 Merck & Co., Inc.

13.4 Novartis

13.5 AstraZeneca Plc

13.6 Pfizer Inc

13.7 Eli Lilly and Company

13.8 Johnson & Johnson

13.9 Amgen Inc.

Not able to find data you are looking for? Ask our Research Analyst.

Reports
Ideas That Generate Results

media citation

get in touch

Reports Ideas That Generate Results

media citation

get in touch

Reports
Ideas That Generate Results